1. Immobilized Recombinant Human IL-18 Bpa Protein (rp169678) at 2.0 μg/mL can bind Recombinant Human IL-18 Protein (rp156177) with the EC50 of 24.67 ng/mL. 2. Measured by its binding ability in a functional ELISA. Immobilized human IL-18 (rp156177) at 2.0 μg/mL can bind GSK 1070806 (anti-IL-18) (Ab177855).
Purity: >95%, by SDS-PAGE visualized with Coomassie® Blue Staining Description: Interleukin-18 (IL-18) is a proinflammatory cytokine in the IL-1 family that exerts distinct immune effects depending on the local cytokine environment. It is expressed as a 24 kDa precursor by endothelial and epithelial cells, keratinocytes, gamma δ T cells, and phagocytes. The precursor is activated intracellularly by Caspase-1 mediated proteolysis to release the 17 kDa mature cytokine. The precursor can also be released by necrotic cells for extracellular cleavage by multiple proteases. IL-18 activation is induced by infection or tissue damage and contributes to disease pathology in chronic inflammation. IL-18 binds to the widely expressed IL-18 R alpha which recruits IL-18 R beta to form the signaling receptor complex. Its bioactivity is negatively regulated by interactions with IL-18 binding proteins and virally encoded IL-18BP homologs. In the presence of IL-12 or IL-15, IL-18 enhances anti-viral Th1 immune responses by inducing IFN-gamma production and the cytolytic activity of CD8+ T cells and NK cells. In the absence of IL-12 or IL-15, however, IL-18 promotes production of the Th2 cytokines IL-4 and IL-13 by CD4+ T cells and basophils. In the presence of IL-1 beta or IL-23, IL-18 induces the antigen-independent production of IL-17 by gamma δ T cells and CD4+ T cells. IL-18 also promotes myeloid dendritic cell maturation and triggers neutrophil respiratory burst. In cancer, IL-18 exhibits diverse activities including enhancing anti-tumor immunity, inhibiting or promoting angiogenesis, and promoting tumor cell metastasis. Mature human IL-18 shares approximately 63% amino acid sequence identity with mouse and rat IL-18. Alternative splicing in human ovarian cancer generates an isoform that is resistant to Caspase-1 activation. A cell surface form can be expressed on M-CSF induced macrophages and released in response to bacterial endotoxin.
1. Immobilized Recombinant Human IL-18 Bpa Protein (rp169678) at 2.0 μg/mL can bind Recombinant Human IL-18 Protein (rp156177) with the EC50 of 24.67 ng/mL. 2. Measured by its binding ability in a functional ELISA. Immobilized human IL-18 (rp156177) at 2.0 μg/mL can bind GSK 1070806 (anti-IL-18) (Ab177855).
17.8 kDa, under reducing condition; 17.8 kDa, under non-reducing condition
分子类型
蛋白质
产品线
生物产品
储存与运输
物理形态
冻干(Lyophilized)
储存缓冲液
Lyophilized from PBS, pH7.4
复溶
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute at 1.0 mg/mL in sterile distilled water. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.
储存条件
-20°C储存,避免反复冻融
运输条件
超低温运输
稳定性与储存
在 -20°C 下可稳定保存 1 年。避免冷冻/解冻循环。
图片
Recombinant Human IL-18 protein (rp156177) - ELISA Immobilized Recombinant Human IL-18 protein (rp156177) at 2.0 μg/mL can bind GSK 1070806 (anti-IL-18) (Ab177855) with the EC50 of 481.8 ng/mL.
Recombinant Human IL-18 Protein (rp156177) - SDS-PAGE 3 μg/lane of Recombinant Human IL-18 Protein was resolved with SDS-PAGE under reducing (R) and non-reducing (N) conditions and visualized by Coomassie® Blue staining, showing a band at 17.8 kDa.
Recombinant Human IL-18 Protein (rp156177) - Binding Activity Immobilized Recombinant Human IL-18 Bpa Protein (rp169678) at 2.0 μg/mL can bind Recombinant Human IL-18 Protein (rp156177) with the EC50 of 24.67 ng/mL.
ZJ24F0606566
危险品化学品经营许可证（带存储）